| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/12/1999 | WO1999040225A1 Immediate early genes and methods of use therefor |
| 08/12/1999 | WO1999040220A2 Method of screening therapeutic agents |
| 08/12/1999 | WO1999040207A1 HUMAN HEPARANASE POLYPEPTIDE AND cDNA |
| 08/12/1999 | WO1999040202A1 NF-λB ACTIVATION INHIBITORS TARGETING ON TAK1 AND METHOD FOR IDENTIFYING THE SAME |
| 08/12/1999 | WO1999040201A1 Protein |
| 08/12/1999 | WO1999040199A2 A novel fungal protein critical for expression of fungal proteins |
| 08/12/1999 | WO1999040198A2 Identification, production and use of staphylokinase derivatives with reduced immunogenicity and/or reduced clearance |
| 08/12/1999 | WO1999040197A2 Variants of the angiogenic factor vascular endothelial cell growth factor: vegf |
| 08/12/1999 | WO1999040196A1 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| 08/12/1999 | WO1999040195A1 Mammalian receptor proteins; related reagents and methods |
| 08/12/1999 | WO1999040192A1 Human receptor gpr14, and a method of finding agonist and antagonist to human and rat gpr14 |
| 08/12/1999 | WO1999040191A1 Dnas or genes participating in parkinson's disease |
| 08/12/1999 | WO1999040190A1 Human tsc403 gene and human ing1l gene |
| 08/12/1999 | WO1999040188A2 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations |
| 08/12/1999 | WO1999040186A1 Optimized antisense oligonucleotides complementary to dna methyltransferase sequences |
| 08/12/1999 | WO1999040185A1 Cytotoxic heteromeric protein combinatorial libraries |
| 08/12/1999 | WO1999040184A1 Dendritic enriched secreted lymphocyte activation molecule |
| 08/12/1999 | WO1999040183A1 Human serine protease and serpin polypeptides |
| 08/12/1999 | WO1999040119A1 Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it |
| 08/12/1999 | WO1999040117A1 THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOF |
| 08/12/1999 | WO1999040116A1 Process for expression of thyroid stimulating hormone receptor |
| 08/12/1999 | WO1999040115A2 COMPOSITIONS AND METHODS TO INHIBIT FORMATION OF THE C5b-9 COMPLEX OF COMPLEMENT |
| 08/12/1999 | WO1999040113A2 Lipopeptides containing an interferon fragment and uses thereof in pharmaceutical compositions |
| 08/12/1999 | WO1999040112A1 Neuroprotective peptides and uses thereof |
| 08/12/1999 | WO1999040111A1 The aiolos gene |
| 08/12/1999 | WO1999040110A1 Breast cancer resistance protein (bcrp) and the dna which encodes it |
| 08/12/1999 | WO1999040109A2 Recombinant mistletoe lectines |
| 08/12/1999 | WO1999040108A1 New compound |
| 08/12/1999 | WO1999040107A2 Method of promoting keratinocyte proliferation |
| 08/12/1999 | WO1999040106A2 Use of angiotensin analogues for promoting erythropoiesis |
| 08/12/1999 | WO1999040104A1 Neokine protein and nucleic acid molecules and uses therefor |
| 08/12/1999 | WO1999040100A1 45 human secreted proteins |
| 08/12/1999 | WO1999039747A1 Bipapcitide-based pharmaceutical compositions for imaging and treating thrombi |
| 08/12/1999 | WO1999039743A2 Method of promoting hepatic cell proliferation |
| 08/12/1999 | WO1999039741A2 Systemic delivery of serum stable plasmid lipid particles for cancer therapy |
| 08/12/1999 | WO1999039740A2 Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| 08/12/1999 | WO1999039737A1 Preventives/remedies for inflammatory intestinal disease |
| 08/12/1999 | WO1999039736A2 DELIVERY OF IMMUNOGENIC MOLECULES VIA HBsAg PARTICLES |
| 08/12/1999 | WO1999039732A1 Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections |
| 08/12/1999 | WO1999039731A1 Copolymer compositions for oral delivery |
| 08/12/1999 | WO1999039730A1 Oral preparations containing peptides promoting the secretion of growth hormone |
| 08/12/1999 | WO1999039729A2 Use of heregulin as an epithelial cell growth factor |
| 08/12/1999 | WO1999039728A2 Methods of inducing hair growth and coloration |
| 08/12/1999 | WO1999039727A1 Costimulatory blockade and mixed chimerism in allotransplantation |
| 08/12/1999 | WO1999039726A1 Costimulatory blockade and mixed chimerism in transplantation |
| 08/12/1999 | WO1999039724A1 Treatment of bony defects with osteoblast precursor cells |
| 08/12/1999 | WO1999039722A2 Compositions and methods for separating lens epithelial cells and preventing posterior capsular opacification |
| 08/12/1999 | WO1999039720A1 Compositions and methods for modulating cytokine release in response to genotoxic agents |
| 08/12/1999 | WO1999039702A2 Method for regulating size and growth of vascularized normal tissue |
| 08/12/1999 | WO1999039700A1 Pharmaceutical compositions in form of nanoparticles comprising lipidic substances and amphiphilic substances and related preparation process |
| 08/12/1999 | WO1999039582A1 Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (prrsv) |
| 08/12/1999 | WO1999031233A8 Polypeptides, polynucleotides and uses thereof |
| 08/12/1999 | WO1999031230A3 Oligophrenin-1, its expression product, and the diagnostic and therapeutic applications thereof |
| 08/12/1999 | WO1999029339A3 Prevention and/or treatment of allergic conditions |
| 08/12/1999 | WO1999028460A3 Molecules interacting with apoptin |
| 08/12/1999 | WO1999028344A3 Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment |
| 08/12/1999 | WO1999028343A3 Hydrophobically-modified protein compositions and methods |
| 08/12/1999 | WO1999027955A3 Treatment of established chronic infections and cancers |
| 08/12/1999 | WO1999027088A3 Novel gene and protein expressed in neural and pancreatic tissues |
| 08/12/1999 | WO1999025378A9 Immunoglobulin molecules having a synthetic variable region and modified specificity |
| 08/12/1999 | WO1999024063A9 Compositions providing for increased igf-i solubility |
| 08/12/1999 | WO1999022759A9 Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules |
| 08/12/1999 | WO1999021574A9 Enhancement of morphogen activity |
| 08/12/1999 | WO1999004820A3 Cytolysis of target cells by superantigen conjugates inducing t-cell activation |
| 08/12/1999 | WO1998058633A3 Microdose therapy of vascular conditions by no donors |
| 08/12/1999 | WO1998053850A3 Compositions and means for the treatment of burns and other cutaneous traumas |
| 08/12/1999 | WO1998048784A3 Method and composition for modulating amyloidosis |
| 08/12/1999 | DE19805385C1 Milk-derived peptides that stimulate Bifidobacterium bifidus |
| 08/12/1999 | DE19805334A1 Verfahren zur Entwicklung eines pharmazeutischen Wirkstoffes A method of developing a pharmaceutical active ingredient |
| 08/12/1999 | DE19804742A1 Treatment of hepatitis C virus infection and associated liver cancer with hydrolytic enzyme and flavonoid |
| 08/12/1999 | DE19804210A1 Rekombinante Mistellektine Recombinant mistletoe |
| 08/12/1999 | DE19801265C1 Inhibierung von CD95-unabhängiger Apoptose bei AIDS Inhibiting CD95-independent apoptosis in AIDS |
| 08/12/1999 | CA2751655A1 Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (prrsv) |
| 08/12/1999 | CA2321175A1 Method of screening therapeutic agents |
| 08/12/1999 | CA2320625A1 45 human secreted proteins |
| 08/12/1999 | CA2320492A1 A novel fungal protein critical for expression of fungal proteins |
| 08/12/1999 | CA2320490A1 Neuroprotective peptides and uses thereof |
| 08/12/1999 | CA2320483A1 Methods of inducing hair growth and coloration |
| 08/12/1999 | CA2320416A1 New compound |
| 08/12/1999 | CA2320359A1 Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (prrsv) |
| 08/12/1999 | CA2320144A1 Neokine protein and nucleic acid molecules and uses therefor |
| 08/12/1999 | CA2320098A1 Compositions and methods to inhibit formation of the c5b-9 complex of complement |
| 08/12/1999 | CA2319764A1 Costimulatory blockade and mixed chimerism in transplantation |
| 08/12/1999 | CA2319720A1 Cytotoxic heteromeric protein combinatorial libraries |
| 08/12/1999 | CA2319693A1 Identification, production and use of staphylokinase derivatives with reduced immunogenicity and/or reduced clearance |
| 08/12/1999 | CA2319664A1 Variants of the angiogenic factor vascular endothelial cell growth factor: vegf |
| 08/12/1999 | CA2319644A1 Human serine protease and serpin polypeptides |
| 08/12/1999 | CA2319567A1 Compositions and methods for modulating cytokine release in response to genotoxic agents |
| 08/12/1999 | CA2319565A1 Pharmaceutical compositions in form of nanoparticles comprising lipidic substances and amphiphilic substances and related preparation process |
| 08/12/1999 | CA2319468A1 Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| 08/12/1999 | CA2319448A1 Costimulatory blockade and mixed chimerism in allotransplantation |
| 08/12/1999 | CA2319421A1 Preventives/remedies for inflammatory intestinal disease |
| 08/12/1999 | CA2319356A1 Composition and methods for treatment of hiv infection |
| 08/12/1999 | CA2319236A1 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| 08/12/1999 | CA2319097A1 Dendritic enriched secreted lymphocyte activation molecule |
| 08/12/1999 | CA2319086A1 Optimized antisense oligonucleotides complementary to dna methyltransferase sequences |
| 08/12/1999 | CA2318857A1 Use of heregulin as an epithelial cell growth factor |
| 08/12/1999 | CA2316860A1 Three-dimensional structures and models of fc receptors and uses thereof |
| 08/11/1999 | EP0935001A1 Novel vegf-like factors |
| 08/11/1999 | EP0935000A2 Orphan receptor |